- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04470999
Changes in Cellular Immune Profile During COVID-19 Infection
Cellular Immune Profile Changes in Individuals With Active or Past COVID-19 Infection
Clinical specimens are collected from individuals either recovered from or with active SARS-CoV-2 infection to support process and analytical development for a potential cell-based immunotherapy in preclinical research, SRPH-CVD-01.
SRPH-CVD-01 is an allogeneic cell-based immunotherapy candidate to be investigated in a subsequent clinical trial under a future FDA IND to treat people suffering from COVID-19.
Enrolled participants provide a venous blood specimen (up to 40mL) to be used in preclinical studies and research and development of SRPH-CVD-01. Subjects may eventually be asked to undergo leukapheresis for peripheral blood mononuclear cell (PBMC) collection and their specimens will be used to further develop the SRPH-CVD-01 cell product, including a cGMP compliant process to be applied under the future FDA IND.
Study Overview
Detailed Description
This protocol is to collect blood and PBMC specimens from individuals with active of past COVID-19 infection. The first blood draw will be done at the first study visit and if eligible, the second collection will be done via leukapheresis at the second visit. The leukapheresis procedures will follow the facility's standard operating procedures and protocol requirements for leukapheresis.
Donors will be males or females between and including the ages of 18 years and 60 years. Volunteers will provide written informed consent and meet all inclusion and exclusion criteria. Each participant can be in the study for up to 180 days (6 months).
The study will be conducted in accordance with human research for the purposes of obtaining clinical specimens for research. There is no endpoint for this study, however, data collected from this study will include, but not be limited to, gender, demographics, medical history, clinical laboratory values, and volume of the blood collected. The data will be summarized in future studies reporting results from a future clinical trial under FDA IND.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90067
- Seraph Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male of female aged 18-60
- Documented current or past (max 3 months prior) diagnosis of COVID19
- Participants who has not participated in a cell or gene therapy trial for COVID19
Exclusion Criteria:
- Uncontrolled SARS symptoms
- Oxygen saturation (Pulse Ox) < 90%
- Uncontrolled diabetes
- Uncontrolled hypertension
- Active DIC, bleeding or coagulopathy which cannot be corrected with minimal intervention
- Symptomatic, uncontrolled or severe intercurrent illness that would compromise the ability to tolerate blood collection or leukapheresis procedure
- Systemic chemotherapy less than or equal to 2 weeks (6 weeks for clofarabine or nitrosoureas) or radiation therapy less than or equal to 3 weeks prior to leukapheresis
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test at screening
- Any patient that in the opinion of the investigator is not medically stable to undergo the leukapheresis procedure or will not comply with the visit schedules or procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
Venous blood and apheresis collection will be conducted
|
Blood collection and PBMC collection via apheresis machine will be conducted
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cellular immune system profiling
Time Frame: Up to 20 days
|
After the initial venous blood draw, the blood samples will be tested to measure the absolute count and percentage of B cells, monocytes, CD4+ and CD8+ T cells, gammadelta T (gdT) cells, CD3+CD56+ natural killer T (NKT) cells, and natural killer (NK) cells in total PBMCs. Data will describe the range of each cell population across participants. |
Up to 20 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Innate immune system profiling
Time Frame: Up to 100 days
|
Innate immune system cells (gdT, NKT, and NK) will be assessed for their SARS-CoV-2 antiviral activity by stimulation and immunophenotyping. Data will report the antiviral phenotypic characteristics of these cells. |
Up to 100 days
|
Expansion of virus-specific innate immune cells
Time Frame: Up to 100 days
|
Virus-specific innate immune cells that are relevant to SRPH-CVD-01 clinical product candidate will be expanded under various conditions to assess their therapeutic and protective potential against COVID-19. Data will report the expansion rate of SRPH-CVD-01 cells. These cell will also help validate the assays and processes for the development of the SRPH-CVD-01 cell product to be used in a future clinical trials. |
Up to 100 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SRPH-CVD-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Leukapheresis
-
University Hospital, Basel, SwitzerlandCompleted
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)Unknown
-
University of California, San FranciscoRecruiting
-
M.D. Anderson Cancer CenterRecruitingLymphomas | B-cell LymphomasUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedDiamond Blackfan AnemiaUnited States
-
Polyphor Ltd.CompletedMyeloproliferative Disorders | Adult Acute Lymphoblastic Leukemia in Remission | Chronic Lymphocytic Leukemia (CLL) | Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukemia in Remission | Chronic Myelogenous Leukemia (CML) | Multiple Myeloma (MM) | Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease...United States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
Washington University School of MedicineBioLineRx, Ltd.CompletedMultiple Myeloma | Hodgkin Disease | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | Hodgkin's Disease | Hodgkins DiseaseUnited States
-
Memorial Sloan Kettering Cancer CenterTerminated
-
Northwestern UniversityTerminatedEnd Stage Liver DiseaseUnited States